Removal of phosphate from lipid a as a strategy to detoxify lipopolysaccharide

Shock

Volumn 18, Issue 6, 2002, Pages 561-566

  Bentala, Hafida ^a   Verweij, Willem R ^b   Huizinga Van Der Vlag, Ali ^b   Van Loenen Weemaes, Annemiek M ^b   Meijer, Dirk K F ^b   Poelstra, Klaas ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NONE

Author keywords

Alkaline phosphatase; Endotoxin; Nitric oxide; RAW 264.7 cells; Reactive oxygen species; Sepsis; TNF

Indexed keywords

EID: 0013239491     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200212000-00013     Document Type: Article

References (31)

1. Hancock RE, Scott MG: The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 97:8856-8861, 2000.
2. van Langevelde P, Kwappenberg KM, Groeneveld PH, Mattie H, van Dissel JT: Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob Agents Chemother 42:739-743, 1998.
3. Kilbourn RG, Griffith OW, Gross SS: Pathogenetic mechanisms of septic shock. N Engl J Med 329:1427-1428, 1993.
4. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy [see Comments]. Ann Intern Med 113:227-242, 1990.
5. Bahrami S, Redl H, Yao YM, Schlag G: Involvement of bacteria/endotoxin translocation in the development of multiple organ failure. In: Rietschel ET, Wagner H, eds. Pathology of septic shock. Berlin: Springer-Verlag Berlin, 1996, pp 239-258.
6. Mammen EF: The haematological manifestations of sepsis: J Antimicrob Chemother 41(Suppl A):17-24, 1998.
7. Griffin GE: Cytokines involved in human septic shock - the model of the Jarisch-Herxheimer reaction. J Antimicrob Chemother 41(Suppl A):25-29, 1998.
8. Dinarello CA. Cytokines as mediators in the pathogenesis of septic shock. In Rietschel ET, Wagner H (eds): Pathology of septic shock. Berlin: Springer-Verlag, 1996, pp 133-165.
9. Hack CE, Aarden LA, Thijs LG: Role of cytokines in sepsis. Adv Immunol 66:101-195, 1997.
10. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273:934-941, 1995.
11. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA: A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029-1032, 1991.
12. Baumgartner JD, Heumann D, Gerain J, Weinbreck P, Grau GE, Glauser MP: Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 171:889-896, 1990.
13. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RM: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group [see Comments]. Crit Care Med 23:994-1006, 1995.
14. Gazzano Santoro H, Meszaros K, Birr C, Carroll SF, Theofan G, Horwitz AH, Lim E, Aberle S, Kasler H, Parent JB: Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 62:1185-1191, 1994.
15. der Mohlen MA, van Deventer SJ, Levi M, van den EB, Wedel NI, Nelson BJ, Friedmann N, ten Cate JW: Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood 85:3437-3443, 1995.
16. Poelstra K, Bakker WW, Klok PA, Hardonk MJ, Meijer DK: A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest 76:319-327, 1997.
17. Wy CA, Goto M, Young RI, Myers TF, Muraskas J: Prophylactic treatment of endotoxic shock with monophosphoryl lipid A in newborn rats. Biol Neonate 77:191-195, 2000.
18. Yao Z, Foster PA, Gross GJ: Monophosphoryl lipid A protects against endotoxic shock via inhibiting neutrophil infiltration and preventing disseminated intravascular coagulation. Circ Shock 43:107-114, 1994.
19. Astiz ME, Rackow EC, Still JG, Howell ST, Cato A, Von Eschen KB, Ulrich JT, Rudbach JA, McMahon G, Vargas R: Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med 23:9-17, 1995.
20. Poelstra K, Bakker WW, Klok PA, Kamps JAAM, Hardonk MJ, Meijer DKF: Dephosphorylation of endotoxin by alkaline phosphatase in vivo. Am J Pathol 151:1163-1169, 1997.
21. Morton RK: Separation and purification of enzymes associated with insoluble particles. Nature 166:1092, 1950.
22. McComb RB, Bowers GN, Posen S: Isoenzymes. In Alkaline phosphatase. New York: Plenum Press, 1979, pp 373-524.
23. Hirano S: Migratory responses of PMN after intraperitoneal and intratracheal administration of lipopolysaccharide. Am J Physiol 270:L836-L845, 1997.
24. Poelstra K, Hardonk MJ, Koudstaal J, Bakker WW: Intraglomerular platelet aggregation and experimental glomerulonephritis. Kidney Int 37:1500-1508, 1990.
25. Novikoff AB: Enzyme localizations with Wachstein-Meisel procedures: real or artifact. J Histochem Cytochem 15:353-354, 1967.
26. Van den Broek L, Wierda JMKH, Smeulers NJ, Proost JH: Pharmacodynamics and pharmacokinetics of an infusion of org 9487, a new short-acting steroidal neuromuscular blocking agent. Br J Anaesth 73:331-335, 1994.
27. Domar U, Nilsson B, Baranov V, Gerdes U, Stigbrand T: Expression of intestinal alkaline phosphatase in human organs. Histochemistry 98:359-364, 1992.
28. Gustafson GL, Rhodes MJ: A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock. Biochem Biophys Res Commun 182:269-275, 1992.
29. Nolan JP: Intestinal endotoxins as mediators of hepatic injury - an idea whose time has come again. Hepatology 10:887-891, 1989.
30. Fourrier F, Jourdain M, Tournoys A, Gosset P, Mangalaboyi J, Chopin C: Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock. Shock 10:364-370, 1998.
31. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.